A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...

The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.

An 800% increase in licensing deal values indicates growing confidence in mRNA technology, but some vaccine producers are ...

A British drugmaker, GlaxoSmithKline (GSK), has sued American pharmaceutical company Moderna claiming it violated patent ...

Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused ...

However, recent lawsuits filed by GSK against mRNA vaccine producers Pfizer, BioNTech and most recently (15 October) Moderna, have put the licensing of mRNA-based pharmaceuticals in the spotlight.

Recent health news highlights various topics including Abbott's profit rise due to medical device sales, Trump's IVF comments ...

Key developments in the health sector include Abbott's profit boost from medical sales, the UK's assisted dying law debate, Donald Trump's reproductive remarks, BAT's synthetic nicotine launch, ...

Bronchiectasis is a clinical condition defined as a chronic, abnormal dilation of the bronchi accompanied by classical ...